MedPath

Gruppo Italiano Malattie EMatologiche dell'Adulto

๐Ÿ‡ฎ๐Ÿ‡นItaly
Ownership
Private
Employees
-
Market Cap
-
Website

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

Not Applicable
Not yet recruiting
Conditions
Minimal Residual Disease
AML, Adult
Interventions
Diagnostic Test: MRD assessment
First Posted Date
2023-10-19
Last Posted Date
2024-04-10
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
225
Registration Number
NCT06090786

Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression

Not yet recruiting
Conditions
Chronic Lymphocytic Leukemia
Interventions
Other: Observation
First Posted Date
2023-10-16
Last Posted Date
2024-04-10
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
73
Registration Number
NCT06084923

Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life

Active, not recruiting
Conditions
DLBCL - Diffuse Large B Cell Lymphoma
First Posted Date
2023-09-07
Last Posted Date
2024-07-25
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
170
Registration Number
NCT06026644
Locations
๐Ÿ‡ฎ๐Ÿ‡น

Aou Di Bologna - Policlinico S. Orsola-malpighi - Uoc Ematologia, Bologna, Italy

๐Ÿ‡ฎ๐Ÿ‡น

AOU Careggi - SOD terapie cellulari e Medicina Trasfusionale, Firenze, Italy

๐Ÿ‡ฎ๐Ÿ‡น

Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Ad Indirizzo Oncologico, Palermo, Italy

and more 10 locations

Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment

Recruiting
Conditions
Multiple Myeloma
Diagnosis
First Posted Date
2023-09-07
Last Posted Date
2025-03-14
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
736
Registration Number
NCT06028087
Locations
๐Ÿ‡ฎ๐Ÿ‡น

Fondazione Policlinico Universitario A. Gemelli IRCCS UOC Servizio e DH di Ematologia, Roma, Italy

Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO

Recruiting
Conditions
Bacterial Infections
Viral Infection
Fungal Infection
Infections
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia, Adult
Acute Lymphoblastic Leukemia, in Relapse
First Posted Date
2023-09-06
Last Posted Date
2024-04-11
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
158
Registration Number
NCT06025682
Locations
๐Ÿ‡ฎ๐Ÿ‡น

UOC Ematologia Fondazione Policlinico Universitario A.Gemelli, Roma, Italy

Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study

Recruiting
Conditions
Relapse
B-cell Non Hodgkin Lymphoma
Refractory Lymphoma
First Posted Date
2023-07-03
Last Posted Date
2023-12-29
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
96
Registration Number
NCT05927558
Locations
๐Ÿ‡ฎ๐Ÿ‡น

Ematologia Istituto Nazionale Tumori, Milano, Italy

Real World Evidence of Fedratinib Effectiveness in MF

Recruiting
Conditions
Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
First Posted Date
2023-06-01
Last Posted Date
2024-02-08
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
93
Registration Number
NCT05883904
Locations
๐Ÿ‡ฎ๐Ÿ‡น

Ematologia FONDAZIONE IRCCS CA' GRANDA, OSPEDALE MAGGIORE POLICLINICO, Milano, Italy

Novel Approaches to Target MECOM/EVI1 in AML

Not Applicable
Recruiting
Conditions
AML, Adult
First Posted Date
2023-05-03
Last Posted Date
2023-12-29
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
24
Registration Number
NCT05839392
Locations
๐Ÿ‡ฎ๐Ÿ‡น

Ematologia, Piacenza, Italy

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Recruiting
Conditions
Indolent B-Cell Non-Hodgkin Lymphoma
COVID-19
Chronic Lymphocytic Leukemia
First Posted Date
2023-04-07
Last Posted Date
2023-11-28
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
954
Registration Number
NCT05803395
Locations
๐Ÿ‡ฎ๐Ÿ‡น

UOC Ematologia AO Cosenza, Cosenza, Italy

๐Ÿ‡ฎ๐Ÿ‡น

Ematologia AOU S.Anna, Ferrara, Italy

๐Ÿ‡ฎ๐Ÿ‡น

Ematologia AOU Careggi, Firenze, Italy

and more 12 locations

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Phase 2
Recruiting
Conditions
Chronic Lymphocytic Leukemia
Autoimmune Hemolytic Anemia
Small Lymphocytic Lymphoma
Monoclonal B-Cell Lymphocytosis CLL-Type
Interventions
First Posted Date
2023-01-23
Last Posted Date
2023-12-01
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
45
Registration Number
NCT05694312
Locations
๐Ÿ‡ฎ๐Ÿ‡น

Ematologia Osp Molinette, Torino, Italy

๐Ÿ‡ฎ๐Ÿ‡น

Ematologia Osp Careggi, Firenze, Italy

๐Ÿ‡ฎ๐Ÿ‡น

Ematologia Osp Maggiore della Caritร , Novara, Italy

ยฉ Copyright 2025. All Rights Reserved by MedPath